Boehringer Ingelheim Animal Health USA Inc. v Intervet International B.V. [2022] FCAFC 88Date:Court:Judges:18 May 2022Full Federal Court of AustraliaPerram, Nicholas and Burley...
Pearce IP is proud to announce that four patent practitioners and three trade marks practitioners are ranked amongst the world’s best by WIPR Leaders 2022. Among the 47 patent...
Australian Mud Company Pty Ltd v Globaltech Corporation Pty Ltd & Ors (No 2) [2022] FCA 88(experimental evidence) Australian Mud Company Pty Ltd & Anr...
Jusand Nominees Pty Ltd v Rattlejack Innovations Pty Ltd [2022] FCA 540 Date:Court:Judge:16 May 2022Federal Court of AustraliaRofe JBackground Jusand Nominees Pty Ltd (Jusand)...
Introduction The promotion of medicinal cannabis products presents some specific challenges given that very few such products are approved therapeutic goods on the Australian...
04 May 22 | Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal announced that it plans to expand into high growth areas including...
Illinois Tool Works Inc v Airco Fasteners Pty Ltd [2022] FCA 495 Date:Court:Judge:5 May 2022Federal Court of AustraliaRofe JBackground Illinois Tool Works Inc (ITW) is the owner...
Innovation developed from plants and plant-derived material can be substantial and includes biotech crops, food production, feed, fibres, fuel and pharmaceuticals. However, as...
Hood v Down Under Enterprises International Pty Ltd [2022] FCAFC 69Date:Court:Judges:4 May 2022Full Federal Court of AustraliaYates, Moshinsky and Rofe JJBackground Mr Hood, the...
As medicinal cannabis (MC) becomes more established in the medicinal sector due to regulatory and attitudinal changes, there has been a corresponding worldwide increase in...
Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not registered on the Australian Register of Therapeutic Goods (ARTG). ...
29 Apr 22 | Merck announced that the EC has approved Keytruda® (pembrolizumab) in combination with chemotherapy (with or without bevacizumab) for the treatment of persistent,...
Pearce IP congratulates two of its patent leaders for being recognised by Managing IP (MIP) in its 2022 IP Stars ranking. Two Pearce IP leaders Naomi Pearce and Jacinta...
Rakman International Pty Ltd v Boss Fire & Safety Pty Ltd [2022] FCA 464Date:Court:Judge:29 April 2022Federal Court of AustraliaYates JBackground This judgment deals with...
Depression, anxiety and related disorders are serious conditions whose treatment is - in many cases - not adequately addressed by existing psychiatric or psychological...
Introduction Medicinal cannabis is now widely available in Australia. However, the vast majority of medicinal cannabis products are not registered on the Australian Register of...
21 Apr 22 | AU | Australia’s TGA granted orphan drug designation to Roche’s glofitamab. The TGA also provided approval for Roche to apply for registration using the provisional...
14 Apr 22 | CA | BIOJAMP announced the launch of SIMLANDI™/AVT02 (high-concentration, low volume, citrate-free biosimilar adalimumab) in Canada. JAMP Pharma has exclusive...
We recently reported on the decision in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 in which the Federal Court found certain batches of Juno’s generic parecoxib...
Commissioner of Patents v Thaler [2022] FCAFC 62Date:Court:Judges:13 April 2022Full Court of the Federal Court of AustraliaAllsop CJ, Nicholas, Yates, Moshinsky and Burley...
11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and latex-free biosimilar adalimumab) in Canada. Yuflyma® is approved...
An enlarged bench of the Full Court of the Federal Court has overturned a first instance decision, reported here, by confirming that artificial intelligence (AI) cannot be named...
In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA from threatening patent infringement proceedings against...
Thank you to all our clients who participated in the inaugural 2022 Pearce IP “We Hear You” survey. The responses we received included clients providing over 45% of Pearce IP’s...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
